These guidelines have been developed to enable professionals to assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder, to achieve healthy outcomes for themselves and their fetus or infant. They have been developed in response to requests from organizations, institutions and individuals for technical guidance on the identification and management of alcohol, and other substance use and substance use disorders in pregnant women. They were developed in tandem with the WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy.

Gain guidance and support when treating the high-risk population of women confronting (or battling) opioid-use disorders during pregnancy.

This book provides a first in-depth, comprehensive, and evidenced-based overview of the treatment of substance use disorders in the pregnant patient. It provides readers with materials that will not only aid them in identifying, assessing, and understanding the issues involved in treating these women, but also the practical tools to implement the best practices from comprehensive care programs specializing in this sort of treatment. Each chapter strikes a balance between the best scientific information available and reasoned, clinical wisdom to fill in where evidence-based information is unavailable -- all in a form that is practical and accessible. It is a valuable tool for clinicians and service providers across disciplines.

Fleshes out the story that is dominated by data concerning the effect of drugs on the unborn, by listening to pregnant or recently delivered women who take addictive drugs. Drawing on interviews with 120 such women, two sociologists explore such issues as how they decide whether or not to terminate their pregnancy, what their parents and family members think about the situation, and what options are available to them if they choose to keep the baby but kick the habit. Annotation copyrighted by Book News, Inc., Portland, OR

Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.

Neonatal Formulary provides comprehensive guidance on the safe use of the drugs prescribed during pregnancy and commonly given to babies during labour and delivery, as well as during lactation and the first year of life. Treating the journey from pregnancy to parenthood as a continuous event, the new edition contains updated information on how the drugs affect both mother and baby. The first part of the book focuses on drug storage, drug licensing, and drug prescribing. In addition, it explains to why the metabolism of drugs differs in premature and sick infants, and why the practice of extrapolating doses from adult studies is unsafe. Patient safety, excipients, and therapies that affect drugs are also covered. Part 2 consists of monographs for over 250 drugs that may find use in the neonatal unit, and possibly outside it. Each monograph is divided into sections covering use, pharmacology, treatment, drug interactions or other administration, information, supply and administration, and references. The monographs are evidence-based and include links to the Cochrane Database of Systematic Reviews, and national guidelines. The third part presents information on additional drugs, and groups of drugs, that are often taken by mothers during pregnancy, labour, or during breast feeding. The drugs discussed in this section all affect the foetus or infant. Containing far more detail than is available in the British National Formulary for Children, and with additional online material featuring updates related to specific drugs and dosing, Neonatal Formulary is an essential guide for neonatologists, neonatal nurses, hospital pharmacists, obstetric staff, advanced nurse practitioners and for all health care professionals caring for pregnant women and their infants in the first year of life.